New approach aims to help transplant patients reduce harsh Anti-Rejection drugs
NCT ID NCT02739412
Summary
This study tested whether giving low-dose IL-2 injections to liver transplant patients could boost special immune cells called Tregs. Researchers hoped increasing Tregs might help the body accept the transplanted liver better, potentially allowing patients to reduce their anti-rejection medications. The trial involved 6 stable liver transplant patients who received injections for 4 weeks while researchers monitored their immune cells and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.